High‐Throughput Kinetic Analysis for Target‐Directed Covalent Ligand Discovery
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Cysteine‐reactive small molecules are used as chemical probes of biological systems and as medicines. Identifying high‐quality covalent ligands requires comprehensive kinetic analysis to distinguish selective binders from pan‐reactive compounds. Quantitative irreversible tethering (qIT), a general method for screening cysteine‐reactive small molecules based upon the maximization of kinetic selectivity, is described. This method was applied prospectively to discover covalent fragments that target the clinically important cell cycle regulator Cdk2. Crystal structures of the inhibitor complexes validate the approach and guide further optimization. The power of this technique is highlighted by the identification of a Cdk2‐selective allosteric (type IV) kinase inhibitor whose novel mode‐of‐action could be exploited therapeutically.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, the quantitative irreversible tethering (qIT) method has been reported for screening PPI covalent inhibitors.”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [82]
In the citing paper
“Thus, the FTQ can be a simple and cost-effective assay for screening covalent inhibitors of PPIs.”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [82]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847
Hein, J. E., & Fokin, V. V. (2010) · Chemical Society Reviews · doi:10.1039/b904091a · Cited by 2,198
The history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Fluorescent and colorimetric probes for detection of thiols
Chen, X., Zhou, Y., Peng, X., & Yoon, J. (2010) · Chemical Society Reviews · doi:10.1039/b925092a · Cited by 1,580
A ‘Rule of Three’ for fragment-based lead discovery?
Congreve, M., Carr, R., Murray, C., & Jhoti, H. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02831-9 · Cited by 1,354
Proteome-wide covalent ligand discovery in native biological systems
Backus, K. M., Correia, B. E., Lum, K. M., Forli, S., Horning, B. D., González-Páez, G. E., Chatterjee, S., Lanning, B. R., Teijaro, J. R., Olson, A. J., et al. (2016) · Nature · doi:10.1038/nature18002 · Cited by 940
Fragment-Based Approaches in Drug Discovery and Chemical Biology
Scott, D. E., Coyne, A. G., Hudson, S. A., & Abell, C. (2012) · Biochemistry · doi:10.1021/bi3005126 · Cited by 460
Tethering: Fragment-Based Drug Discovery
Erlanson, D. A., Wells, J. A., & Braisted, A. C. (2004) · Annual Review of Biophysics and Biomolecular Structure · doi:10.1146/annurev.biophys.33.110502.140409 · Cited by 385
Flanagan, M. E., Abramite, J. A., Anderson, D. P., Aulabaugh, A., Dahal, U. P., Gilbert, A. M., Li, C., Montgomery, J., Oppenheimer, S. R., Ryder, T., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501412a · Cited by 320
Chemical Proteomics Identifies Druggable Vulnerabilities in a Genetically Defined Cancer
Bar-Peled, L., Kemper, E. K., Suciu, R. M., Vinogradova, E. V., Backus, K. M., Horning, B. D., Paul, T. A., Ichu, T.-A., Svensson, R. U., Olucha, J., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.051 · Cited by 262
Cited by
Rapid Covalent-Probe Discovery by Electrophile-Fragment Screening
Resnick, E., Bradley, A., Gan, J., Douangamath, A., Krojer, T., Sethi, R., Geurink, P. P., Aimon, A., Amitai, G., Bellini, D., et al. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b02822 · Cited by 335
Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update
Hillebrand, L., Liang, X. J., Serafim, R. A. M., & Gehringer, M. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01825 · Cited by 199
Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015–2019)
Sánchez-Martínez, C., Lallena, M. J., Sanfeliciano, S. G., & de Dios, A. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.126637 · Cited by 194
10 Years Into the Resurgence of Covalent Drugs
De Vita, E. (2021) · Future Medicinal Chemistry · doi:10.4155/fmc-2020-0236 · Cited by 122
Characterising covalent warhead reactivity
Martin, J. S., MacKenzie, C. J., Fletcher, D., & Gilbert, I. H. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.04.002 · Cited by 125
Fragment-based covalent ligand discovery
Lu, W., Kostic, M., Zhang, T., Che, J., Patricelli, M. P., Jones, L. H., Chouchani, E. T., & Gray, N. S. (2021) · RSC Chemical Biology · doi:10.1039/d0cb00222d · Cited by 136
Covalent fragment libraries in drug discovery
Keeley, A. B., Petri, L., Ábrányi‐Balogh, P., & Keserű, G. M. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.03.016 · Cited by 118
Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures
Cheng, W., Yang, Z., Wang, S., Li, Y., Han, W., Tian, X., & Kan, Q. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.01.003 · Cited by 113
The design and development of covalent protein-protein interaction inhibitors for cancer treatment
Cheng, S.-S., Yang, G.-J., Wang, W., Leung, C.-H., & Ma, D.-L. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00850-0 · Cited by 98
Development of CDK2 and CDK5 Dual Degrader TMX‐2172
Teng, M., Jiang, J., He, Z., Kwiatkowski, N. P., Donovan, K. A., Mills, C. E., Victor, C., Hatcher, J. M., Fischer, E. S., Sorger, P. K., et al. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202004087 · Cited by 80
Zaidman, D., Gehrtz, P., Filep, M., Fearon, D., Gabizon, R., Douangamath, A., Prilusky, J., Duberstein, S., Cohen, G., Owen, C. D., et al. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.05.018 · Cited by 88
Fragment-to-Lead Medicinal Chemistry Publications in 2018
Erlanson, D. A., de Esch, I. J. P., Jahnke, W., Johnson, C. N., & Mortenson, P. N. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01581 · Cited by 80
Heidrich, J., Sperl, L. E., & Boeckler, F. M. (2019) · Frontiers in Chemistry · doi:10.3389/fchem.2019.00009 · Cited by 67
A Photoaffinity‐Based Fragment‐Screening Platform for Efficient Identification of Protein Ligands
Grant, E. K., Fallon, D. J., Hann, M. M., Fantom, K. G. M., Quinn, C. J., Zappacosta, F., Annan, R. S., Chung, C., Bamborough, P., Dixon, D. P., et al. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202008361 · Cited by 64
Reactivity of Covalent Fragments and Their Role in Fragment Based Drug Discovery
McAulay, K., Bilsland, A. E., & Bon, M. (2022) · Pharmaceuticals · doi:10.3390/ph15111366 · Cited by 60
Oyedele, A.-Q. K., Ogunlana, A. T., Boyenle, I. D., Adeyemi, A. O., Temionu, O. R., Adelusi, T. I., Abdul-Hammed, M., Elegbeleye, O. E., & Odunitan, T. T. (2022) · Molecular Diversity · doi:10.1007/s11030-022-10523-4 · Cited by 59
Functionalized Scout Fragments for Site-Specific Covalent Ligand Discovery and Optimization
Crowley, V. M., Thielert, M., & Cravatt, B. F. (2021) · ACS Central Science · doi:10.1021/acscentsci.0c01336 · Cited by 54
Reaction screening in multiwell plates: high-throughput optimization of a Buchwald–Hartwig amination
Cook, A., Clément, R., & Newman, S. G. (2021) · Nature Protocols · doi:10.1038/s41596-020-00452-7 · Cited by 52
Multicomponent reaction–derived covalent inhibitor space
Sutanto, F., Shaabani, S., Neochoritis, C. G., Zarganes‐Tzitzikas, T., Patil, P., Ghonchepour, E., & Dömling, A. S. S. (2021) · Science Advances · doi:10.1126/sciadv.abd9307 · Cited by 51
Exploring ligand binding pathways on proteins using hypersound-accelerated molecular dynamics
Araki, M., Matsumoto, S., Bekker, G., Isaka, Y., Sagae, Y., Kamiya, N., & Okuno, Y. (2021) · Nature Communications · doi:10.1038/s41467-021-23157-1 · Cited by 48
Chen, J., Pang, L., Wang, W., Wang, L., Zhang, J. Z. H., & Zhu, T. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1591304 · Cited by 44
Applications of Reactive Cysteine Profiling
Backus, K. M. (2018) · Current topics in microbiology and immunology · doi:10.1007/82_2018_120 · Cited by 43
Learning About Allosteric Drugs and Ways to Design Them
Tan, Z. W., Tee, W.-V., & Berezovsky, I. N. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167692 · Cited by 43
Synthesis and Configurational Assignment of Vinyl Sulfoximines and Sulfonimidamides
Craven, G. B., Briggs, E. L., Zammit, C. M., McDermott, A., Greed, S., Affron, D. P., Leinfellner, C., Cudmore, H., Tweedy, R., Luisi, R., et al. (2021) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.1c00373 · Cited by 36
Self-citationDenis, J. D. S., Chessari, G., Cleasby, A., Cons, B. D., Cowan, S., Dalton, S. E., East, C., Murray, C. W., O’Reilly, M., Peakman, T. M., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01044 · Cited by 34
Expedited SARS‐CoV‐2 Main Protease Inhibitor Discovery through Modular ‘Direct‐to‐Biology’ Screening
Wilders, H., Biggs, G. S., Rowe, S. M., Cawood, E. E., Riziotis, I. G., Rendina, A. R., Grant, E. K., Pettinger, J., Fallon, D. J., Skehel, M. J., et al. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202418314 · Cited by 33
Proj, M., Knez, D., Sosič, I., & Gobec, S. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.03.008 · Cited by 32
Covalent hits and where to find them
Lucas, S. C. C., Blackwell, J. H., Hewitt, S. H., Semple, H., Whitehurst, B. C., & Xu, H. (2024) · SLAS DISCOVERY · doi:10.1016/j.slasd.2024.01.003 · Cited by 31
Inhibitors and PROTACs of CDK2: challenges and opportunities
Zeng, Y., Ren, X., Jin, P., Fan, Z., Liu, M., Zhang, Y., Li, L., Zhuo, M., Wang, J., Li, Z., et al. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2376655 · Cited by 30
Kinetic mechanisms of covalent inhibition
McWhirter, C. L. (2021) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2020.11.001 · Cited by 29
In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease
Xiong, M., Nie, T., Shao, Q., Li, M., Su, H., & Xu, Y. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114130 · Cited by 29
Biophysical screening in fragment-based drug design: a brief overview
Robson‐Tull, J. (2018) · Bioscience Horizons The International Journal of Student Research · doi:10.1093/biohorizons/hzy015 · Cited by 29
Cyclin D-CDK4 Disulfide Bond Attenuates Pulmonary Vascular Cell Proliferation
Knight, H., Abis, G., Kaur, M., Green, H. L. H., Krasemann, S., Hartmann, K., Lynham, S., Clark, J. E., Zhao, L., Ruppert, C., et al. (2023) · Circulation Research · doi:10.1161/circresaha.122.321836 · Cited by 27
Covalent Kinase Inhibitors: An Overview
Gehringer, M. (2020) · Topics in medicinal chemistry · doi:10.1007/7355_2020_103 · Cited by 27
Faber, E. B., Wang, N., & Georg, G. I. (2020) · Biology of Reproduction · doi:10.1093/biolre/ioaa107 · Cited by 26
Zhou, Y., Shen, W., Peng, J., Deng, Y., & Li, X. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116328 · Cited by 24
Emerging approaches to CDK inhibitor development, a structural perspective
Hope, I., Endicott, J., & Watt, J. E. (2023) · RSC Chemical Biology · doi:10.1039/d2cb00201a · Cited by 24
Huang, Y., Wei, L., Han, X., Chen, H., Ren, Y., Xu, Y., Song, R., Rao, L., Chen, S., Peng, C., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111749 · Cited by 24
HCovDock: an efficient docking method for modeling covalent protein–ligand interactions
Wu, Q., & Huang, S. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac559 · Cited by 23
Craven, G. B., Affron, D. P., Kösel, T., Wong, T. L., Jukes, Z., Liu, C., Morgan, R. M. L., Armstrong, A., & Mann, D. J. (2020) · ChemBioChem · doi:10.1002/cbic.202000457 · Cited by 21
Self-citationJung, Y., Noda, N., Takaya, J., Abo, M., Toh, K., Tajiri, K., Cui, C., Zhou, L., Sato, S., & Uesugi, M. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.1c00824 · Cited by 20
Identification of the first structurally validated covalent ligands of the small GTPase RAB27A
Jamshidiha, M., Lanyon‐Hogg, T., Sutherell, C. L., Craven, G. B., Tersa, M., Vita, E. D., Brustur, D., Pérez‐Dorado, I., Hassan, S., Petracca, R., et al. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00225b · Cited by 19
Self-citationZhong, Z., Hocking, B. J. W., Brown, C. P., Ma, T., White, A., Mann, D. J., Armstrong, A., & Bull, J. A. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202420028 · Cited by 18
Self-citationDevelopments and challenges in hit progression within fragment-based drug discovery
Grosjean, H., & Biggin, P. C. (2026) · Nature Communications · doi:10.1038/s41467-026-68941-z · Cited by 17
Qin, B., Craven, G. B., Hou, P., Chesti, J., Lu, X.-R., Child, E. S., Morgan, R. M. L., Niu, W., Zhao, L., Armstrong, A., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.06.002 · Cited by 17
Self-citationComparative reactivity profiling of cysteine-specific probes by chemoproteomics
Yang, F., Chen, N., Wang, F., Jia, G., & Wang, C. (2022) · Current Research in Chemical Biology · doi:10.1016/j.crchbi.2022.100024 · Cited by 16
Frankovich, T. V., McCann, H. M., Hoffman, K. S., & Rullo, A. F. (2025) · ACS Central Science · doi:10.1021/acscentsci.5c00699 · Cited by 13
Covalent fragment libraries in drug discovery—Design, synthesis, and screening methods
Hocking, B. J. W., Armstrong, A., & Mann, D. J. (2023) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2023.10.003 · Cited by 13
Self-citationCOOKIE-Pro: covalent inhibitor binding kinetics profiling on the proteome scale
Lin, H., Yang, B., Ding, L., Yang, Y., Holt, M. V., Jung, S. Y., Zhang, B., Wang, M. C., & Wang, J. (2025) · Nature Communications · doi:10.1038/s41467-025-63491-2 · Cited by 12
Advanced technologies for screening and identifying covalent inhibitors
Guo, Y., Wen, S., Tong, A., & Wang, Y. (2024) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2024.117833 · Cited by 12
Recent Development of CDK2 Inhibitors as Anticancer Drugs: An Update (2015–2023)
Jin, Y., Lu, H., Hu, G., Hou, X., & Hao, F. (2024) · Pharmaceutical Fronts · doi:10.1055/s-0044-1789577 · Cited by 11
Huang, F., Hu, H., Wang, K., Peng, C., Xu, W., Zhang, Y., Gao, J., Liu, Y., Zhou, H., Huang, R., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00372 · Cited by 11
Best Practices for Design and Characterization of Covalent Chemical Probes
Gabizon, R., Resnick, E., & London, N. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781839160745-00069 · Cited by 11
Vinyl sulfonamide synthesis for irreversible tethering via a novel α-selenoether protection strategy
Craven, G. B., Affron, D. P., Raymond, P. N., Mann, D. J., & Armstrong, A. (2018) · MedChemComm · doi:10.1039/c8md00566d · Cited by 11
Self-citationThe covalent docking software landscape: features and applications in drug design
Singh, N., Vayer, P., & Villoutreix, B. O. (2025) · Briefings in Bioinformatics · doi:10.1093/bib/bbaf697 · Cited by 10
Normalizing Covalent Potency for Electrophilicity with Ligand Reactivity Efficiency
Horning, B. D., Kingston, C., Simon, G. M., Patricelli, M. P., Weinstein, D. S., & Cook, B. N. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01803 · Cited by 10
Shraga, A., Resnick, E., Gabizon, R., & London, N. (2021) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2021.04.001 · Cited by 10
Ji, X., Cui, X., Li, Z., Choi, T., Wang, Y., Xiao, W. J., Zhao, Y., Zha, J., Zhang, J., Chen, H., et al. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c01369 · Cited by 10
A Photoaffinity‐Based Fragment‐Screening Platform for Efficient Identification of Protein Ligands
Grant, E. K., Fallon, D. J., Hann, M. M., Fantom, K. G. M., Quinn, C. J., Zappacosta, F., Annan, R. S., Chung, C., Bamborough, P., Dixon, D. P., et al. (2020) · Angewandte Chemie · doi:10.1002/ange.202008361 · Cited by 8
Giarolla, J., Holdaway, K. A., Nazari, M., Aiad, L., Sarkar, B., & Georg, G. I. (2025) · Future Medicinal Chemistry · doi:10.1080/17568919.2025.2463868 · Cited by 5
Development of CDK2 and CDK5 Dual Degrader TMX‐2172
Teng, M., Jiang, J., He, Z., Kwiatkowski, N. P., Donovan, K. A., Mills, C. E., Victor, C., Hatcher, J. M., Fischer, E. S., Sorger, P. K., et al. (2020) · Angewandte Chemie · doi:10.1002/ange.202004087 · Cited by 5
Expedited SARS‐CoV‐2 Main Protease Inhibitor Discovery through Modular ‘Direct‐to‐Biology’ Screening
Wilders, H., Biggs, G. S., Rowe, S. M., Cawood, E. E., Riziotis, I. G., Rendina, A. R., Grant, E. K., Pettinger, J., Fallon, D. J., Skehel, M. J., et al. (2024) · Angewandte Chemie · doi:10.1002/ange.202418314 · Cited by 4
Culletta, G., Almerico, A. M., & Tutone, M. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673331207241019085108 · Cited by 3
Wang, F., Zheng, X., Li, K., Wei, Y., Liu, Y., Hu, G., Bao, T., & Yang, J. (2026) · arXiv (Cornell University) · doi:10.48550/arxiv.2603.12845 · Cited by 3
Zhong, Z., Hocking, B. J. W., Brown, C. P., Ma, T., White, A., Mann, D. J., Armstrong, A., & Bull, J. A. (2024) · Angewandte Chemie · doi:10.1002/ange.202420028 · Cited by 2
Self-citationDeciphering covalent kinase inhibitor binding landscape through structural kinome profiling
Zhao, Z., & Bourne, P. E. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118872 · Cited by 2
Allosteric Inhibition of PKMYT1 Induces a Unique, Inactive ATP Binding Site Conformation
Herrington, N. B., Khamrui, S., Zhao, Y., Lansiquot, C., Wu, R., Pandey, G., Lazarus, M. B., & Schlessinger, A. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.6c05178 · Cited by 2
Vita, E. D., Thomas, A., Brustur, D., Tersa, M., Petracca, R., Vadodaria, S., Briggs, D. A., Houghton, J. W., Lanyon‐Hogg, T., Craven, G. B., et al. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.6c08927 · Cited by 2
Self-citationChemical proteomics of reactive molecules
Wang, L., & Yao, X. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821433-6.00008-8 · Cited by 2
Quantitative Irreversible Tethering (qIT) for Target-directed Covalent Fragment Screening
Craven, G. B., Mann, D. J., & Armstrong, A. (2020) · BIO-PROTOCOL · doi:10.21769/bioprotoc.3855 · Cited by 1
Self-citationNanostructured Photonic Chips for High Throughput Biomolecule Sensing
Makela, M. (2023) · OakTrust (Texas A&M University Libraries)
Proj, M. (2023) · Repository of the University of Ljubljana (University of Ljubljana)
Development of Allosteric Inhibitors Against Cyclin-Dependent Kinase 2 (CDK2)
Georg, G. I., & Georg, G. I. (2026) · Springer eBooks · doi:10.1007/978-3-032-12320-6_2
A FRET-Based Assay for Assessing Covalent Warhead Reactivity
Valaka, A. P., Benitez‐Martin, C., Andréasson, J., & Grøtli, M. (2026) · ACS Omega · doi:10.1021/acsomega.5c12902
Discovery of Covalent Wild-Type Isocitrate Dehydrogenase 1 (IDH1) Inhibitors Targeting Cys269Preprint
Brown, C. C., Harmer, E. O., Azam, A., Sharp, C., Horrell, S., Bull, J. A., Armstrong, A., & Mann, D. J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.24.753951
Self-citationBindingDB (2025) · UC San Diego · doi:10.7270/q2vm4hvh
BindingDB (2021) · UC San Diego · doi:10.7270/q2c53qdz
BindingDB Entry 50008548: Fragment-to-Lead Medicinal Chemistry Publications in 2018.
BindingDB (2021) · UC San Diego · doi:10.7270/q2zg6wm7
BindingDB (2021) · UC San Diego · doi:10.7270/q23f4t3t
Bilyard, M. K., & Srinivasan, B. (2026) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2026.10.017
Metadata
- Authors
- Craven, G. B., Affron, D. P., Allen, C. E., Matthies, S., Greener, J. G., Morgan, R. M. L., Tate, E. W., Armstrong, A., & Mann, D. J.
- Affiliations
- Imperial College London (GB)
- Corresponding author
- Mann, David J.
- ORCID
- Venue
- Angewandte Chemie International Edition
- Publisher
- Wiley
- Published
- 2018-03-26
- Volume
- 57
- Issue
- 19
- Pages
- 5257-5261
- ISSN
- 1433-7851 (ISSN-L)
- 1521-3773
- PMC
- PMC5947712
- OpenAlex
- W2791999156
- Cited by
- 73
- References
- 32
- Citations by year
- 2026: 7 · 2025: 6 · 2024: 9 · 2023: 3 · 2022: 11 · 2021: 12 · 2020: 15 · 2019: 7 · 2018: 3
- FWCI
- 4.20
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Angewandte Chemie International Edition (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Spiral (Imperial College London) (submittedVersion, other-oa)
- Spiral (Imperial College London) (submittedVersion)
- Imperial College Research Computing Service Data Repository
- Funders
- Engineering and Physical Sciences Research Council (EP/F500416/1)
- Biotechnology and Biological Sciences Research Council (BB/J014575/1)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Click Chemistry and Applications
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- kinetic selectivity, CDK2, allosteric kinase inhibitors, chemical probes, high-throughput screening
- MeSH terms
- Cysteine, Kinetics, Ligands, Molecular Structure, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 2, Small Molecule Libraries, Drug Discovery, High-Throughput Screening Assays
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.